● Recruiting

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Condition: GBM · Sponsor: Ever Supreme Bio Technology Co., Ltd.

PhasePhase 2

Planned participants24

Who can joinAll sexes, 20 Years to 75 Years

Healthy volunteersNo

About this study

This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme

This description comes directly from the study's public registry record.

Talk to the study team

Wen-Liang Huang · 0422052121 · wlhuang@ever-supreme.com.tw

Always discuss trial participation with your own doctor first.

Locations (3)

Taichung Veterans General Hospital	Taichung, Non-US, Taiwan	Recruiting
Chang-Gung Memorial Hospital at Lin-Ko	Taoyuan, Non-US, Taiwan	Recruiting
China Medical University Hospital	Taichung, Taiwan	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04115761